高剂量四价流感疫苗在儿童中的安全性与免疫原性:随机对照II期剂量探索试验
该II期随机对照试验在美国和加拿大纳入661名6月龄至<18岁健康儿童,比较标准剂量四价流感疫苗、三种高剂量四价流感疫苗和佐剂三价流感疫苗的安全性与免疫原性。结果显示高剂量疫苗不增加非征集不良事件,反应原性略高但多为1-2级,60µg HA/株高剂量疫苗可提高血凝抑制和血清中和抗体几何平均滴度,尤其在6月龄至<3岁儿童中。
要点
- 高剂量四价流感疫苗在儿童中安全性良好,未报告治疗相关严重不良事件或死亡。
- 60µg HA/株高剂量疫苗较标准剂量疫苗显著提高抗体几何平均滴度,6月龄至<3岁儿童提升最明显。
- 高剂量疫苗反应原性略高于标准剂量,但多数征集反应为1级或2级。
核心结论
- 高剂量四价流感疫苗(60µg HA/株)在儿童中提供改善的免疫原性且不影响疫苗安全性。
研究设计与样本
- 随机、改良双盲、活性对照II期剂量探索试验,在美国和加拿大纳入661名6月龄至<18岁健康儿童。
- 受试者接受1或2剂肌肉注射标准剂量四价流感疫苗(15µg HA/株)、三种剂量水平的高剂量四价流感疫苗(30、45、60µg HA/株)或佐剂三价流感疫苗(7.5µg HA/株)。
主要发现
- 非征集不良事件发生率各剂量组相似,未报告治疗相关严重不良事件或死亡。
- 高剂量四价流感疫苗反应原性略高于标准剂量四价流感疫苗,但多数征集反应为1级或2级。
- 血凝抑制几何平均滴度随血凝素剂量增加而升高,尤其在6月龄至<3岁儿童中。
- 60µg高剂量疫苗组6月龄至<18岁受试者较标准剂量组的血凝抑制几何平均滴度比值(95%CI)为:A/H1N1 1.35(0.94, 1.94)、A/H3N2 2.51(1.77, 3.55)、B/Victoria 1.60(1.17, 2.18)、B/Yamagata 1.51(1.13, 2.03)。
- 6月龄至<3岁儿童中60µg高剂量疫苗组较标准剂量组的血凝抑制几何平均滴度比值(95%CI)为:A/H1N1 4.24(2.05, 8.76)、A/H3N2 3.14(1.53, 6.44)、B/Victoria 2.04(1.10, 3.77)、B/Yamagata 1.92(1.08, 3.41);血清中和抗体几何平均滴度比值(95%CI)为:A/H1N1 170(84.6, 340)、A/H3N2 7.13(4.90, 10.4)、B/Victoria 35.8(22.1, 58.1)、B/Yamagata 22.7(14.7, 35.0)。
临床怎么用
- 在6月龄至<18岁儿童中,高剂量四价流感疫苗(60µg HA/株)可考虑用于提高免疫原性,尤其对6月龄至<3岁儿童免疫应答提升更显著。
- 接种高剂量四价流感疫苗时需关注反应原性略高于标准剂量疫苗,但多数反应为轻度至中度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quadrivalent high-dose inactivated influenza vaccine (Fluzone® High-Dose Quadrivalent, IIV4-HD) was licensed in the USA in 2019 for adults ≥ 65 years of age. This Phase II study examined safety and immunogenicity of 3 dose formulations of IIV4-HD in healthy children. In a randomized, modified double-blind, active-controlled trial in the USA and Canada, 661 children aged 6 months through < 18 years received 1 or 2 doses intramuscularly of standard-dose quadrivalent influenza vaccine (IIV4-SD; 15 µg HA/strain), IIV4-HD at 3 dose levels (30, 45, and 60 µg HA/strain), or adjuvanted trivalent influenza vaccine (aIIV3, 7.5 µg HA/strain). Rates of unsolicited AEs were similar irrespective of dose. No treatment-related serious adverse events or deaths were reported. Reactogenicity was slightly higher for IIV4-HD than IIV4-SD, although most solicited reactions were grade 1 or 2. Hemagglutination inhibition (HAI) and seroneutralization antibody titers were measured 28-35 days after each dose. Geometric mean HAI titers increased with increasing hemagglutinin dose, especially in children 6 months through < 3 years. For IIV4-HD 60 µg, in participants 6 months through < 18 years of age, the geometric mean titer ratio (95% confidence interval) versus IIV4-SD was 1.35 (0.94, 1.94) for A/H1N1, 2.51 (1.77, 3.55) for A/H3N2, 1.60 (1.17, 2.18) for B/Victoria, and 1.51 (1.13, 2.03) for B/Yamagata. The GMT ratio (95% confidence interval) for IIV4-HD 60 µg versus IIV4-SD was highest for participants 6 months through < 3 years of age: 4.24 (2.05, 8.76) for A/H1N1, 3.14 (1.53, 6.44) for A/H3N2, 2.04 (1.10, 3.77) for B/Victoria, and 1.92 (1.08, 3.41) for B/Yamagata; similarly, seroneutralization antibody GMT ratio was highest in these participants: 170 (84.6, 340) for A/H1N1, 7.13 (4.90, 10.4) for A/H3N2, 35.8 (22.1, 58.1) for B/Victoria, and 22.7 (14.7, 35.0) for B/Yamagata. This study showed that IIV4-HD (60 µg HA/strain) provides improved immunogenicity without affecting vaccine safety in children.
引用
- Chang LJ, Anderson EJ, Jeanfreau R, et al. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial. Vaccine. 2021. PMID: 33610374. doi:10.1016/j.vaccine.2021.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。